Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are standard therapies for higher-risk (HR)-MDS, the relative prognostic performance of existing prognostic tools among patients with HR-MDS rece...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Leukemia
Asıl Yazarlar: Zeidan, AM, Sekeres, MA, Garcia-Manero, G, Steensma, DP, Zell, K, Barnard, J, Ali, NA, Zimmerman, C, Roboz, G, DeZern, A, Nazha, A, Jabbour, E, Kantarjian, H, Gore, SD, Maciejewski, JP, List, A, Komrokji, R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775363/
https://ncbi.nlm.nih.gov/pubmed/26464171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.283
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller